(BFM Stock Exchange) – The manufacturer of infectious disease vaccines announced on Monday, August 18 that the Canadian health authority extended to adolescents the use of this vaccine, called IXCHIQ. This makes it possible to maintain the dynamics of the title which resumes more than 85% over a month.

Valneva is one of the few values of the Parisian coast to animate this August. After delivering his half -yearly results last week, the specialist in infectious disease vaccines announced on Monday, August 18, a new authorization for IXCHIQ, his chikungunya vaccine on Monday, August 18.

The Canadian Health Authority, Health Canada, has approved the extension of the use of IXCHIQ for people over the age of 12. The Valneva vaccine had already been approved in Canada for adults, that is to say people over the age of 18, in April 2024.

“This authorization marks an important new step for our vaccine, because chikungunya continues to represent a significant risk for people living in endemic regions or going there. (…) We expect regulatory decisions of other countries where wider access will help protect the population and reduce the burden of this potentially disabling disease that continues to spread in regions until then spared” Carlos Jaramillo, medical director of Valneva, quoted in a press release.

>> Access our exclusive graphic analyzes, and enter into the confidence of the trading portfolio

An annual sales peak up to 200 million euros

Chikungunya is a viral disease transmitted by mosquitoes and causing fevers, strong joint and muscle pain, headache, nausea, fatigue or rashes. The virus was identified in more than 110 countries and 3.7 million cases were identified on the American continent between 2013 and 2023.

The Valneva IXCHIQ vaccine is currently marketed in the European Union in Canada, in the United Kingdom and in the United States. Last April, Brazil in turn approved IXCHIQ, which then constituted the first global approval of a country where the disease is endemic, that is to say that it is constantly present on the territory.

Valneva also obtained the extension of the use of IXCHIQ among adolescents aged 12 to 17 years last April in the European Union. The group also submitted a request for approval of this extension to the United States.

Last year, Valneva had generated its first sales on IXCHIQ for a total of 3.7 million euros. In the first half of 2025, the group announced last week that it had drawn 7.5 million euros in revenue from the vaccine against chikungunya. “In the medium term (4-5 years), and according to our estimates, Ixchiq could generate a peak of annual sales around 200 million euros,” said Mohamed Kaabouni, analyst at Portzamparc in April.

An increase of almost 90% over a month

On the Paris Stock Exchange, the announcement of the approval of the extension of the vaccine in Canada brings the Valneva action. The title takes 7.7% this Monday August 18 around 10:30 am. This new progression allows the value to consolidate an impressive rally over a month, the action earning more than 86% over 30 days. This brings the increase in the title to the whole of 2025 to 138.7%.

Valneva also takes on Monday, first place in the SBF 120 record place over all of 2025, doubling the operators of retirement home Emeis (ex-Orpea, +136.8%) and Clariane (ex-Korian, +126.1%).

The good dynamic of the Valneva action has been caused by a series of positive announcements. The title was notably carried out by the fact that the European Union and the United States turned upwards their restrictions on the use of IXCHIQ for the elderly.

These two authorities had temporarily restricted the use of the vaccine, the time to lead a review after serious undesirable effects occurred on Reunion Island. The French department experienced an important epidemic last spring, which led the authorities to call on the Valneva vaccine with the delivery of 40,000 doses.

The half -yearly results delivered last week by the company had also been well received by the market. The action had taken 8.7% on the day of the publication and then 18.7% the next day.

Valneva had reported a gross loss of operating operating much less pronounced than expected by analysts, thanks to its efforts on costs, and had confirmed the calendar of the results of clinical trials expected in the coming months.

The company had notably indicated that the results of the phase III clinical trial (last step before a potential marketing) evaluating its VLA15 vaccine against Lyme disease were expected after the end of October.

This vaccine is co -developed with the American Pfizer and Valneva plans to request a marketing authorization from the American and European health authorities in 2026.

“If the vaccine is approved and marketed, Valneva could receive from Pfizer up to $ 143 million in payments linked to the first stages of product marketing, sales royalties ranging from 14% to 22% as well as step -based sales payments that can reach $ 100 million,” said the company.